SOPHiA GENETICS SA SOPH
Set alert
7.14 USD -0.49 -6.39%
As of Nov 2, 1:22 PM ET
7.11 Day range 7.69
3.83 52-week range 8.98
- YTD
- +52.94%
- 1 year
- +42.84%
- Open
- 7.66
- Prev close
- 7.63
- Mkt cap
- 607.81M
- Vol
- 188.09K
- Avg vol
- 606.18K
- EPS
- -1.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.11
- High
- 7.69
- Forward P/E
- -4.09
- Beta
- 1.03
- Short ratio
- 0.89
- Inst. own
- 53.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 3.43
- 200-d avg
- 4.18
- 1y target
- 7.00
1D chart
Signals (14)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | 11:47 AM | 1 hour ago |
| MACD: Buy Signal | 11:26 AM | 1 hour ago |
| RSI: Oversold | 11:11 AM | 2 hours ago |
| MACD: Sell Signal | 11:09 AM | 2 hours ago |
| RSI: Oversold | 11:08 AM | 2 hours ago |
| MACD: Buy Signal | 11:03 AM | 2 hours ago |
| RSI: Oversold | 10:54 AM | 2 hours ago |
| SMA: Bullish | 10:34 AM | 2 hours ago |
| SMA: Bearish | 10:33 AM | 2 hours ago |
| MACD: Sell Signal | 10:30 AM | 2 hours ago |
| SMA: Bullish | 10:22 AM | 3 hours ago |
| SMA: Bearish | 10:21 AM | 3 hours ago |
| SMA: Bullish | 10:06 AM | 3 hours ago |
| RSI: Oversold | 9:45 AM | 3 hours ago |
Key statistics
- Market cap
- 219.91M
- Enterprise value
- 152.48M
- Trailing P/E
- 0.00
- Forward P/E
- -4.09
- PEG ratio
- 0.00
- Price / sales
- 3.41
- Price / book
- 1.94
- EPS (TTM)
- -1.09
- Beta
- 1.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -110.71%
- Revenue (TTM)
- 64.49M
- Revenue growth
- -2.80%
- Free cash flow
- -26.18M
- Total cash
- 95.79M
- Total debt
- 31.67M
- Return on equity
- -52.51%
- Shares outstanding
- 66.44M
- Short % of float
- 0.05%
- 50-day average
- 3.43
- 200-day average
- 4.18
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 7.00 -2.0% downside
Now 7.14
- Target (low)
- 5.00
- Target (mean)
- 7.00
- Target (high)
- 11.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy1
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.15.
Financials — quick view
SOPH Revenue — quarterly 23.31M
SOPH Net income — quarterly -22.36M
SOPH EPS — quarterly -0.30
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.24 | -0.28 | -0.04 | -16.67% |
| Aug 6, 2024 | Jun 1, 2024 | -0.28 | -0.23 | +0.05 | +17.86% |
| Aug 6, 2024 | Jun 1, 2024 | -0.28 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.25 | -0.21 | +0.04 | +16.00% |
| May 7, 2024 | Mar 1, 2024 | -0.25 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.25 | -0.37 | -0.12 | -48.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Craig-Hallum | init | — | Buy |
| Aug 7, 2024 | RBC Capital | main | Outperform | Outperform |
| Jun 27, 2024 | Guggenheim | init | — | Buy |
| Mar 6, 2024 | BTIG | main | Buy | Buy |
| Mar 6, 2024 | RBC Capital | reit | Outperform | Outperform |
| Jan 12, 2024 | RBC Capital | reit | Outperform | Outperform |
About SOPHiA GENETICS SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- Switzerland
- Website
- sophiagenetics.com
News
- SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026
- HC Wainwright & Co. Reiterates Buy on Sophia Genetics, Maintains $14 Price Target
- SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SOPHiA GENETICS (NASDAQ:SOPH) Insider Manuela Valente Sells 4,240 Shares of Stock
- SOPHiA GENETICS (NASDAQ:SOPH) CFO George Cardoza Sells 1,592 Shares of Company Stock
- SOPHiA GENETICS SA (NASDAQ:SOPH) Receives Average Rating of “Hold” from Analysts
- SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
- When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
Your note
Sign in to keep a note on SOPH — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Generation Investment Management LLP | 10.39% | 6,789,560 | 22.47M | Sep 29, 2024 |
| Banque Pictet & Cie SA | 3.43% | 2,243,240 | 7.43M | Sep 29, 2024 |
| Akre Capital Management, LLC | 3.42% | 2,237,504 | 7.41M | Sep 29, 2024 |
| UBS Asset Management Americas Inc | 3.40% | 2,220,322 | 7.35M | Sep 29, 2024 |
| Principal Financial Group, Inc. | 2.23% | 1,455,142 | 4.82M | Sep 29, 2024 |
| Alta Wealth Advisors LLC | 2.16% | 1,409,160 | 4.66M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Principal Small Cap Fund | 0.73% | 476,200 | 1.58M | Jul 30, 2024 |
| 1290 Fds-1290 Essex Small Cap Growth Fd | 0.09% | 56,119 | 185.75K | Jul 30, 2024 |
| Principal Var Contracts Fund-SmallCap Account | 0.08% | 52,700 | 174.44K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index ETF | 0.07% | 48,902 | 161.87K | Oct 30, 2024 |
| Federated Hermes Prudent Bear Fund | 0.06% | 37,406 | 123.81K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 40,573 | 134.30K | Oct 30, 2024 |